MAXYGEN INC Financials

Maxygen swings to profit in Q2

MAXYGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

Maxygen Reports Second Quarter 2010 Financial Results
[Business Wire] - REDWOOD CITY, Calif.----Maxygen, Inc. , a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements, today announced financial and business results for the quarter ended June 30, 2010.

Maxygen Announces Expiration of Cangene's Option to License MAXY-G34 for Acute Radiation Syndrome
[Business Wire] - REDWOOD CITY, Calif.----Maxygen, Inc. , a biotechnology company focused on the development of improved protein drugs, today announced that its option and licensing arrangement with Cangene Corporation has expired.

Perseid Achieves Second Preclinical Milestone under Collaboration with Astellas for CTLA-4 Program
[Business Wire] - REDWOOD CITY, Calif.----Maxygen, Inc. , a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a second preclinical milestone under its collaboration with Astellas Pharma Inc. to co-develop and commercialize next-generation CTLA4-Ig therapeutics.